Breast Cancer Diagnostics Global Market Report 2024

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $4.42 billion in 2023 to $4.8 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. Historically, the growth in the breast cancer diagnostics market can be attributed to a combination of factors. These include heightened awareness and screening campaigns aimed at early detection, the widespread use of mammography screening techniques, continuous technological advancements in diagnostic tools, the integration of genetic testing for a more precise diagnosis, and the adoption of a multidisciplinary approach to tackling breast cancer.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.47 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. Looking ahead, the anticipated growth in the breast cancer diagnostics market is expected to be driven by several key factors. These include the expanding use of personalized medicine to tailor treatments to individual patients, the growing adoption of liquid biopsies as a less invasive diagnostic method, the increasing utilization of advanced 3D mammography (tomosynthesis) for improved accuracy, the integration of artificial intelligence (AI) and machine learning to enhance diagnostic capabilities, and the rising popularity of telemedicine and remote consultations for patient convenience. Additionally, notable trends in the forecast period include continuous advancements in imaging technologies, the ongoing focus on personalized medicine, the widespread adoption of liquid biopsies, and the increasing role of AI and machine learning in breast cancer diagnostics.

The growth of the breast cancer diagnostics market is expected to be driven by the increasing incidence of breast cancer. With breast cancer being the most prevalent form of cancer, affecting approximately 2.1 million women annually and resulting in the highest number of cancer-related deaths among women, the demand for diagnostic equipment is set to rise. Early detection is paramount in improving the prognosis and reducing the mortality rate associated with breast cancer. For example, in January 2022, the American Cancer Society reported an estimated 287,850 new cases of invasive breast cancer and 51,400 cases of DCIS in women in the United States for 2022, with an expected 43,250 breast cancer-related fatalities. Hence, the escalating incidence of breast cancer is projected to fuel the breast cancer diagnostics market.

Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.

The breast cancer diagnostics market research report is one of a series of new reports that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Government initiatives and funding for breast cancer are poised to contribute to the growth of the breast cancer diagnostics market. Government support, through initiatives and financial backing, plays a crucial role in advancing breast cancer research, prevention, and treatment. These programs aim to raise awareness, promote early detection through screening and mammography services, and provide financial aid for underserved communities undergoing breast cancer testing and treatment. In the budget for 2022-23, the Australian Government Department of Health allocated $40.7 million to improve the accessibility of testing and screening services for various cancer types, including a dedicated $9.7 million for breast cancer screening. Consequently, government initiatives and funding initiatives are propelling the breast cancer diagnostics market forward.

The high cost associated with breast cancer diagnosis presents a significant obstacle to the growth of the diagnostics market. The diagnostic phase of breast cancer typically incurs substantial expenses. For instance, in December 2022, the Centers for Disease Control and Prevention revealed that breast cancer has the highest treatment cost among all cancers, accounting for 14% of total cancer treatment expenditures. This high cost of breast cancer diagnosis makes it financially burdensome for many individuals and acts as a deterrent, hindering the expansion of the breast cancer diagnostics market.

In the breast cancer diagnostics market, a significant trend is the continuous advancement in technology, which has led to the development of new diagnostic techniques for breast cancer. One notable innovation is 3D mammography, also known as breast tomosynthesis, which captures multiple images of the breast from various angles and constructs a 3-D model. An example of technological innovation in this field is the introduction of Thermalytix by Niramai, an Indian Health-Tech company, in September 2022. Thermalytix is an automated breast cancer screening and diagnostic tool that combines thermal imaging with artificial intelligence to enhance breast cancer detection and diagnosis.

Key players in the breast cancer diagnostics market are actively engaged in the development of cutting-edge AI-based devices designed to improve diagnostic accuracy and drive market revenues. AI breast cancer diagnostic devices leverage artificial intelligence algorithms to analyze complex medical data and offer valuable diagnostic insights and recommendations. By applying machine learning and data processing techniques, these devices can deliver highly accurate and efficient disease identification. For example, Digistain, a biotech company based in the United Kingdom, launched an AI breast cancer diagnostic tool in December 2022, boasting an accuracy rate of over 99%. This technology, validated through clinical studies and peer reviews, not only expedites diagnoses but also enhances treatment decisions. It holds the potential to significantly reduce waiting times, lower costs, and enable personalized risk assessment, potentially eliminating the need for chemotherapy in some cases. Through the application of machine learning and proprietary optical scans, this device can identify intricate patterns that traditional methods may overlook, providing highly personalized risk evaluations validated with a substantial patient sample.

In January 2021, Hologic, a US-based women's health medtech company, acquired Somatex Medical for $64 million. This strategic acquisition aligns with Hologic's commitment to providing comprehensive solutions for breast healthcare. Somatex Medical, based in Germany, is a renowned provider of breast cancer diagnostic services.

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

North America was the largest region in the breast cancer diagnostics market in 2023. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the breast cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.